A day after the DOJ said it would ease restrictions on medical marijuana, the FDA moves to fast-track some experimental psychedelic drugs for review. They’re looking at three drugs for treatment-resistant depression, major depressive disorder, and PTSD. NBC’s Anne Thompson reports.